Global DNA Microarray Market 2016-2020
About DNA Microarray
A DNA microarray is a collection of microscopic DNA spots that are attached to a solid surface. DNA microarrays allow the simultaneous monitoring of expression of thousands of genes. They can be used for both determination of mRNA levels and for genotyping. Protein microarrays help in monitoring the level of translation of proteins and the testing of enzyme actions. The tool is widely used to ascertain whether a particular individual’s DNA contains a mutation in genes.
Technavio’s analysts forecast the global DNA microarray market to grow at a CAGR of 15.16% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global DNA microarray market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of DNA microarray solutions such as instruments and consumables.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global DNA Microarray Market 2016-2020
Technavio recognizes the following companies as the key players in the global DNA microarray market: Agilent Technologies, Illumina, Merck, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Applied Microarrays, Arrayit, AXO Science, BioCat, BioGenex Laboratories, Biometrix Technology, Cepheid, GE Healthcare, InDevR, LC Sciences, PerkinElmer, Phalanx Biotech, QIAGEN, Takara Bio, and US Biomax.
Commenting on the report, an analyst from Technavio’s team said: “Growing popularity of personalized medicines will be a key trend for market growth. The popularity of DNA microarray technology is growing as it helps in the early detection of diseases, and selection of accurate treatment methods can reduce mortality rates. DNA microarray technology enables researchers to analyze critical biological complications such as the genomic variations and nature of inherited syndromes that cause cardiovascular diseases and cancers.”
According to the report, advances in technology will be a key driver for market growth. Rapid advances in technology related to DNA microarray has equipped related solutions to produce results with high efficiency, accuracy, specificity, and reproducibility in target identification, primary screening, and toxicity study in drug discovery and research. The technological advances in DNA microarray have also enabled solutions to be applied in clinics, commercial laboratories and research institutions, and hospitals to detect DNA and proteins with the motive of disease diagnosis, drug discovery, and disease monitoring that has significantly increased the acceptance and adoption of these solutions.
Further, the report states that the laws and regulations of the approval process for diagnostic devices vary across all countries, which is a major challenge faced by MNCs. In addition, any change in regulatory policies by different governing bodies including National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), and FDA during the product development period could delay the entry of potential products into the market. Many developed countries such as the US, the UK, Germany, France, Japan, Singapore, and South Korea have strict regulations regarding the approval and marketing of diagnostics products.
Agilent Technologies, Illumina, Merck, Thermo Fisher Scientific, Applied Microarrays, Arrayit, AXO Science, BioCat, BioGenex Laboratories, Biometrix Technology, Cepheid, GE Healthcare, InDevR, LC Sciences, PerkinElmer, Phalanx Biotech, QIAGEN, Takara Bio, US Biomax.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook